Literature DB >> 19515028

Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).

M Chitlur1, I Warrier, M Rajpurkar, J M Lusher.   

Abstract

Haemophilia B is an X-linked disorder resulting in coagulation factor IX deficiency. Patients with severe deficiency (<1% factor IX activity) may have significant bleeding complications similar to patients with haemophilia A or factor VIII deficiency. The development of inhibitory antibodies to the missing coagulation factor is a major complication in patients with haemophilia. While the incidence of inhibitors in patients with haemophilia A is higher than that in haemophilia B, the occurrence of allergic and or anaphylactic reactions with the development of inhibitors is unique to haemophilia B patients. Since haemophilia B is a rare bleeding disorder and the incidence of inhibitors is an even rarer entity, a registry was established by Dr Indira Warrier under the auspices of the FVIII/FIX subcommittee of the International Society of Thrombosis and Haemostasis, to gather information on the occurrence and characteristics of patients with inhibitors and also the incidence of allergic and anaphylactic reactions in this group of patients. This is the first report from this registry and helps us to gather some insight on haemophilia B patients with inhibitors and complications related to inhibitor development and difficulties with immune tolerance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19515028     DOI: 10.1111/j.1365-2516.2009.02039.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  30 in total

1.  Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis.

Authors:  Sven Björkman; Victor Ahlén
Journal:  Eur J Clin Pharmacol       Date:  2012-01-27       Impact factor: 2.953

2.  Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.

Authors:  Peter W Collins; Guy Young; Karin Knobe; Faraizah Abdul Karim; Pantep Angchaisuksiri; Claus Banner; Türkiz Gürsel; Johnny Mahlangu; Tadashi Matsushita; Eveline P Mauser-Bunschoten; Johannes Oldenburg; Christopher E Walsh; Claude Negrier
Journal:  Blood       Date:  2014-09-26       Impact factor: 22.113

3.  Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Authors:  Angiola Rocino; Antonio Coppola; Massimo Franchini; Giancarlo Castaman; Cristina Santoro; Ezio Zanon; Elena Santagostino; Massimo Morfini
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

4.  A survey of the management of newborns with severe hemophilia in Canada.

Authors:  Paul C Moorehead; Jamie Ray; Nicholas J Barrowman; Brigitte Lemyre; Robert Klaassen
Journal:  Paediatr Child Health       Date:  2013-04       Impact factor: 2.253

5.  Recurrent episodes of anaphylaxis in a patient with haemophilia B: a case report.

Authors:  Margherita Mauro; Elisa Bonetti; Rita Balter; Giovanni Poli; Simone Cesaro
Journal:  Blood Transfus       Date:  2016-04-28       Impact factor: 3.443

6.  Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed.

Authors:  Karin C Berger; Brian M Feldman; Joan Wasserman; Wolfgang Schramm; Victor Blanchette; Kathelijn Fischer
Journal:  Haematologica       Date:  2016-03       Impact factor: 9.941

7.  The Epidemiology of FVIII Inhibitors in Indian Haemophilia A Patients.

Authors:  Patricia Pinto; Tejashree Shelar; Vidhya Nawadkar; Darshana Mirgal; Alfiya Mukaddam; Preethi Nair; Priyanka Kasatkar; Tejasvita Gaikwad; Shahnaz Ali; Anshul Jadli; Rucha Patil; Anita Parihar; Sharda Shanbhag; Bipin Kulkarni; Kanjaksha Ghosh; Shrimati Shetty
Journal:  Indian J Hematol Blood Transfus       Date:  2014-02-05       Impact factor: 0.900

Review 8.  Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.

Authors:  C H Miller
Journal:  Haemophilia       Date:  2018-02-15       Impact factor: 4.287

9.  Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding.

Authors:  Andrew J Gale; Vikas Bhat; Jean-Luc Pellequer; John H Griffin; Laurent O Mosnier; Annette Von Drygalski
Journal:  Pharm Res       Date:  2016-03-09       Impact factor: 4.200

10.  Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay.

Authors:  B Boylan; A S Rice; A T Neff; M J Manco-Johnson; C L Kempton; C H Miller
Journal:  J Thromb Haemost       Date:  2016-09-17       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.